On 17 September 2025, Formycon announced that Klinge Biopharma, the exclusive holder of the global commercialisation rights for Formycon’s FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), has entered a semi-exclusive licence agreement with French ophthalmology laboratory, Horus Pharma, for the commercialisation of FYB203 (under the brand name Baiama®) in selected European countries.
Under the agreement, Klinge will receive upfront and milestone payments, plus royalties on net sales. Formycon will participate in all payment streams to Klinge, in the mid-single digit to low-double digit percentage range, and will receive additional payments for organising the commercial market supply chain on behalf of Klinge.
FYB203 (aflibercept) received European marketing approval in January 2025 as Baiama® and Ahzantive®. Neither Baiama®/Ahzantive®, nor any of the ten other EU approved aflibercept biosimilars, has been launched in Europe to date.
The agreement between Klinge and Horus follows an earlier semi-exclusive commercialisation agreement between Klinge and Teva Pharmaceuticals for FYB203 covering major parts of Europe (excluding Italy) and Israel, entered in mid-January 2025. Teva will market the product under the Ahzantive® brand name.